We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04953897
Recruitment Status : Recruiting
First Posted : July 8, 2021
Last Update Posted : July 20, 2022
Information provided by (Responsible Party):
Astex Pharmaceuticals, Inc.

Brief Summary:
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 mg and cedazuridine 100 mg in cancer participants with severe renal impairment and cancer participants with normal renal function as matched control subjects. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration is approximately up to 8 weeks.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Myelodysplastic Syndromes Drug: ASTX727 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function
Actual Study Start Date : December 15, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023

Arm Intervention/treatment
Experimental: Group A: Severe Renal Impairment
Cancer participants with severe renal impairment not requiring dialysis (creatinine clearance [CLcr] <30 mL/min/1.73m^2)
Drug: ASTX727
Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Other Name: Oral decitabine and cedazuridine

Active Comparator: Group B: Normal Renal Function
Cancer participants with normal renal function (CLcr ≥80 mL/min/1.73m^2)
Drug: ASTX727
Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Other Name: Oral decitabine and cedazuridine

Primary Outcome Measures :
  1. Pharmacokinetic parameter: 5-day AUCtau [ Time Frame: Day 1 to Day 5 ]
    Cumulative area under the curve (AUC) from Day 1 to Day 5 for decitabine

Secondary Outcome Measures :
  1. Safety: adverse events [ Time Frame: Up to 8 weeks ]
    Percentage of participants with adverse events

  2. Pharmacokinetic parameter: Cmax [ Time Frame: Day 1 to Day 8 ]
    Maximum observed plasma concentration of cedazuridine, cedazuridine epimer, and decibatine

  3. Pharmacokinetic parameter: Tmax [ Time Frame: Day 1 to Day 8 ]
    Time to maximum observed plasma concentration of cedazuridine, cedazuridine epimer, and decibatine

  4. Pharmacokinetic parameter: AUC0-t [ Time Frame: Day 1 to Day 8 ]
    Area under the curve from time 0 (time of dosing) to time t, where t is the last time point with concentrations above the lower limit of quantitation for cedazuridine, cedazuridine epimer, and decitabine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to understand and comply with the study procedures, understand the risks involved in the study, and provide legally effective informed consent before the first study-specific procedure; specifically able to comply with the PK assessment schedule during the first treatment cycle.
  • Participants must have histologically or cytologically confirmed solid tumor or hematologic malignancy that is metastatic or unresectable and for which standard life-prolonging measures are not available.
  • For participants with AML/MDS only:

    1. Cytologically or histologically confirmed diagnosis of AML (except M3 acute promyelocytic leukemia) or MDS according to the 2008 World Health Organization (WHO) classification with the disease being refractory, relapsed, or unresponsive to standard treatment;
    2. Participants with frontline MDS or treatment naïve AML not suitable for induction therapy (eg, age of >75 years, Eastern Cooperative Oncology Group [ECOG] performance status ≥ 2, severe pulmonary disorder, total bilirubin > 1.5x upper limit of normal [ULN]);
    3. Platelet count ≥ 25,000/μL;
    4. Absolute neutrophil count (ANC) ≥ 100 cells/μL.
  • For participants with solid tumors only:

    1. Platelet count ≥ 100,000/μL;
    2. ANC ≥ 1000 cells/μL.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Adequate hepatic function defined as:

    1. Total or direct bilirubin ≤1.5 × upper limit of normal (ULN);
    2. AST and alanine aminotransferase (ALT) ≤2.5 × ULN.
  • Participants must have a body surface area (BSA)-adjusted CLcr using to the Cockcroft-Gault equation:

    1. Patients without renal impairment (Group B): ≥80 mL/min/1.73m²;
    2. Patients with severe renal impairment (Group A): <30 mL/min/1.73m², not requiring dialysis;
    3. CLcr must be stable with <30% deviation allowed from Screening to Baseline (Day -1). Patients shifting outside the prospected renal function category (normal renal function or severe renal function) at Baseline need to be agreed by Astex medical expert whether they are allowed to remain in the original category that was assessed at Screening.
  • No major surgery within 30 days of first administration of oral decitabine and cedazuridine.
  • Life expectancy of at least 3 months.
  • Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group) must not be pregnant or breastfeeding and must have a negative pregnancy test at Screening.
  • Women of childbearing potential* must agree to practice 1 highly effective contraceptive measure of birth control with low user dependency and must agree not to become pregnant for 6 months after completing treatment.
  • Male patients with female partners of childbearing potential must agree to use a male condom and advise his partner to practice 1 highly effective contraceptive measure of birth control (user dependent or with low user dependency) and must agree not to father a child while receiving treatment with oral decitabine and cedazuridine for at least 3 months after completing treatment.

Exclusion Criteria:

  • Treatment with azacitidine or decitabine within 4 weeks before Screening. Prior cytotoxic chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC) counts.
  • Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia, sepsis, or systemic infection during the individual screening period.
  • Treatment with any investigational medicinal product (IMP), investigational therapy, chemotherapy, immunotherapy, or targeted therapy within 2 weeks or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events from previous treatment.
  • Concurrent MDS therapies, including lenalidomide, cyclosporine/tacrolimus, granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, etc. Prior treatment with these agents is permitted, provided that completion is at least 1 week before the first dose of study treatment. Short-term use of G-CSF for febrile neutropenia is permitted at the discretion of the treating physician and should be guided by accepted practice or institutional guidelines. Hematopoietic growth factors will not be routinely used unless cleared by Astex medical expert.
  • Administration of live (attenuated) vaccines within 4 weeks before the first administration of oral decitabine and cedazuridine until after the follow-up visit. Other vaccines, eg, inactivated or RNA-based, may be administered but should not occur from 7 days before first administration of oral decitabine and cedazuridine until after the follow-up visit.
  • High medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the patient at risk of not being able to complete at least 2 cycles of treatment.
  • Conditions which likely promote delayed ventricular repolarization (QT prolongation):

    1. Corrected QT interval (QTc) using Bazett's correction (QTcB) or QTc using Fridericia correction (QTcF) at Screening or Day -1 > 450 ms
    2. History or disposition for torsades des pointes (TdP) (eg, heart failure, hypokalemia, family history of long QT Syndrome)
    3. Concomitant medication that prolong the QT/QTc interval
  • Cardiac abnormalities or unstable cardiovascular conditions:

    1. Unstable ischemic heart disease or severe heart failure (New York Heart Association Class III or IV).
    2. Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg; current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg).
  • Known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the patient to high risk of noncompliance with the protocol.
  • In participants with AML/MDS, rapidly progressive or highly proliferative disease or other criteria that render the patient at high risk of requiring intensive cytotoxic chemotherapy within the next 3 months.
  • Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, that in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of oral decitabine and cedazuridine, or compromise completion of the study or integrity of the study outcomes.
  • Untreated central nervous system (CNS) metastases. Participants with treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks before screening.
  • Positive nasopharyngeal test for SARS-CoV-2 at Screening or Day -1. Participants may be rescreened if they become SARS-CoV-2 negative.
  • Participants infected with human immunodeficiency virus (HIV).
  • Participants with active hepatitis B or hepatitis C infection.
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products).
  • Average intake of more than 24 units of alcohol per week for male participants and 17 units per week for female participants (1 unit of alcohol equals 10 mL of pure alcohol, ie, approximately 250 mL of beer, 75 mL of wine or 25 mL of spirits).
  • Positive drugs of abuse or alcohol test at Screening and Day -1, except for the use of prescribed and medically indicated drugs (eg, benzodiazepines, opiates, or cannabinoids).
  • Donation or loss of more than 500 mL of blood within 60 days prior to the first study drug administration.
  • Hypersensitivity to decitabine, cedazuridine, or any of the excipients in oral decitabine and cedazuridine tablets.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04953897

Layout table for location contacts
Contact: Astex Pharmaceuticals 925-560-0100 clinicaltrials@astx.com

Layout table for location information
Complex Oncology Center - Plovdiv - Base II Recruiting
Plovdiv, Bulgaria
BIO1 Recruiting
Vilnius, Lithuania
Summit Clinical Research s.r.o Recruiting
Bratislava, Slovakia, 831 01
Contact: Principal Investigator         
Summit Clinical Research s.r.o Recruiting
Bratislava, Slovakia
Hospital Universitari Dexeus - Grupo Quirónsalud Recruiting
Barcelona, Spain
Hospital Universitari Arnau de Vilanova Recruiting
Lleida, Spain
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain
Hospital Clínico Universitario Virgen de la Arrixaca Recruiting
Murcia, Spain
Hospital Universitari i Politècnic La Fe Recruiting
Valencia, Spain
Sponsors and Collaborators
Astex Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Astex Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04953897    
Other Study ID Numbers: ASTX727-17
First Posted: July 8, 2021    Key Record Dates
Last Update Posted: July 20, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Bone Marrow Diseases
Hematologic Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors